share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K:重大事件
美股SEC公告 ·  05/15 17:17

Moomoo AI 已提取核心訊息

TransCode Therapeutics, Inc. has announced that the Nasdaq Listing Qualifications Department has stayed its delisting action pending a final decision by a Nasdaq Hearing Panel. The decision follows the company's appeal against the delisting notice received on May 7, 2024, for failing to maintain the minimum bid price requirement of $1.00 per share. TransCode Therapeutics, which had been given until May 6, 2024, to regain compliance, was also found ineligible for a second compliance period due to not meeting the minimum stockholders' equity requirement. The company's common stock will continue to trade on The Nasdaq Capital Market under the symbol 'RNAZ' until the Panel's final decision post the hearing scheduled for June 25, 2024. The company has cautioned that there is no assurance of a successful appeal or that it will regain compliance and remain listed on Nasdaq.
TransCode Therapeutics, Inc. has announced that the Nasdaq Listing Qualifications Department has stayed its delisting action pending a final decision by a Nasdaq Hearing Panel. The decision follows the company's appeal against the delisting notice received on May 7, 2024, for failing to maintain the minimum bid price requirement of $1.00 per share. TransCode Therapeutics, which had been given until May 6, 2024, to regain compliance, was also found ineligible for a second compliance period due to not meeting the minimum stockholders' equity requirement. The company's common stock will continue to trade on The Nasdaq Capital Market under the symbol 'RNAZ' until the Panel's final decision post the hearing scheduled for June 25, 2024. The company has cautioned that there is no assurance of a successful appeal or that it will regain compliance and remain listed on Nasdaq.
TransCode Therapeutics, Inc.宣佈,在納斯達克聽證小組做出最終決定之前,納斯達克上市資格部門暫停其退市行動。該決定是在該公司因未能維持每股1.00美元的最低出價要求而對2024年5月7日收到的除名通知提出上訴之後作出的。在2024年5月6日之前獲准恢復合規的TransCode Therapeutics也因未達到最低股東權益要求而被認定沒有資格進入第二個合規期。該公司的普通股將繼續在納斯達克資本市場上交易,股票代碼爲 “RNAZ”,直到該小組在定於2024年6月25日舉行的聽證會後做出最終決定。該公司警告說,無法保證上訴成功,也無法保證它將恢復合規並繼續在納斯達克上市。
TransCode Therapeutics, Inc.宣佈,在納斯達克聽證小組做出最終決定之前,納斯達克上市資格部門暫停其退市行動。該決定是在該公司因未能維持每股1.00美元的最低出價要求而對2024年5月7日收到的除名通知提出上訴之後作出的。在2024年5月6日之前獲准恢復合規的TransCode Therapeutics也因未達到最低股東權益要求而被認定沒有資格進入第二個合規期。該公司的普通股將繼續在納斯達克資本市場上交易,股票代碼爲 “RNAZ”,直到該小組在定於2024年6月25日舉行的聽證會後做出最終決定。該公司警告說,無法保證上訴成功,也無法保證它將恢復合規並繼續在納斯達克上市。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息